Nanjing Hicin Pharmaceutical Hits Day Low Amid Price Pressure at CNY 31.18

Nanjing Hicin Pharmaceutical Co., Ltd. experienced a significant decline today, with the stock dropping by 11.67% on July 17, 2026. The stock reached an intraday low of CNY 31.18, reflecting a challenging trading environment for the small-cap pharmaceutical company. Over the past week, Nanjing Hicin has seen an 8.92% decrease, and its performance over the last month shows a decline of 18.0%. Year-to-date, the stock has underperformed considerably, with a drop of 37.59%, contrasting sharply with the China Shanghai Composite, which has only fallen by 5.16% during the same period. Despite some positive financial indicators, such as a 25.6% growth in net sales and a 55.88% increase in net profit for the first half of the year, the company has struggled with low profitability metrics, including a Return on Capital Employed (ROCE) of just 4.33%. The stock's high Price to Book ratio of 1.87 and a Return on Equity (ROE) of 5.39% further highlight the challenges faced by Nanjing Hicin in maintaining investor confidence amidst a volatile market.